Cargando…

Tissue Transglutaminase Expression Associates With Progression of Multiple Sclerosis

OBJECTIVE: The clinical course of multiple sclerosis (MS) is variable and largely unpredictable pointing to an urgent need for markers to monitor disease activity and progression. Recent evidence revealed that tissue transglutaminase (TG2) is altered in patient-derived monocytes. We hypothesize that...

Descripción completa

Detalles Bibliográficos
Autores principales:	Sestito, Claudia, Leurs, Cyra E., Steenwijk, Martijn D., Brevé, John J.P., Twisk, Jos W.R., Wilhelmus, Micha M.M., Drukarch, Benjamin, Teunissen, Charlotte E., van Dam, Anne-Marie, Killestein, Joep
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Lippincott Williams & Wilkins 2021
Materias:	Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8105890/ https://www.ncbi.nlm.nih.gov/pubmed/33906937 http://dx.doi.org/10.1212/NXI.0000000000000998

Ejemplares similares

Differential Expression of Tissue Transglutaminase Splice Variants in Peripheral Blood Mononuclear Cells of Primary Progressive Multiple Sclerosis Patients
por: Sestito, Claudia, et al.
Publicado: (2018)

Monocyte-derived tissue transglutaminase in multiple sclerosis patients: reflecting an anti-inflammatory status and function of the cells?
por: Sestito, Claudia, et al.
Publicado: (2017)

Plasma proteome in multiple sclerosis disease progression
por: Malekzadeh, Arjan, et al.
Publicado: (2019)

Is monocyte- and macrophage-derived tissue transglutaminase involved in inflammatory processes?
por: Chrobok, Navina L., et al.
Publicado: (2016)

Cerebrospinal fluid mtDNA concentration is elevated in multiple sclerosis disease and responds to treatment
por: Leurs, Cyra E, et al.
Publicado: (2017)

Characterization of Transglutaminase 2 activity inhibitors in monocytes in vitro and their effect in a mouse model for multiple sclerosis
por: Chrobok, Navina L., et al.
Publicado: (2018)

Tissue Transglutaminase Appears in Monocytes and Macrophages but Not in Lymphocytes in White Matter Multiple Sclerosis Lesions
por: Chrobok, Navina L, et al.
Publicado: (2019)

Correction: Characterization of Transglutaminase 2 activity inhibitors in monocytes in vitro and their effect in a mouse model for multiple sclerosis
por: Chrobok, Navina L., et al.
Publicado: (2018)

The Transglutaminase-2 Interactome in the APP23 Mouse Model of Alzheimer’s Disease
por: Wilhelmus, Micha M. M., et al.
Publicado: (2022)

No Plasmatic Proteomic Signature at Clinical Disease Onset Associated With 11 Year Clinical, Cognitive and MRI Outcomes in Relapsing-Remitting Multiple Sclerosis Patients
por: Bridel, Claire, et al.
Publicado: (2018)

Absence of tissue transglutaminase reduces amyloid‐beta pathology in APP23 mice
por: Wilhelmus, Micha M. M., et al.
Publicado: (2022)

Dynamic functional connectivity as a neural correlate of fatigue in multiple sclerosis
por: Tijhuis, Floris B., et al.
Publicado: (2021)

Blood platelet RNA enables the detection of multiple sclerosis
por: Sol, Nik, et al.
Publicado: (2020)

Catalytically active tissue transglutaminase colocalises with Aβ pathology in Alzheimer’s disease mouse models
por: Wilhelmus, Micha M. M., et al.
Publicado: (2016)

In vivo evaluation of two tissue transglutaminase PET tracers in an orthotopic tumour xenograft model
por: van der Wildt, Berend, et al.
Publicado: (2018)

Serum contactin-1 as a biomarker of long-term disease progression in natalizumab-treated multiple sclerosis
por: van Lierop, Zoë YGJ, et al.
Publicado: (2021)

Tissue transglutaminase in astrocytes is enhanced by inflammatory mediators and is involved in the formation of fibronectin fibril-like structures
por: Espitia Pinzón, Nathaly, et al.
Publicado: (2017)

Monocyte behaviour and tissue transglutaminase expression during experimental autoimmune encephalomyelitis in transgenic CX3CR1(gfp/gfp) mice
por: Chrobok, Navina L., et al.
Publicado: (2016)

Tissue Transglutaminase Promotes Early Differentiation of Oligodendrocyte Progenitor Cells
por: Espitia Pinzon, Nathaly, et al.
Publicado: (2019)

Neurofilament-light and contactin-1 association with long-term brain atrophy in natalizumab-treated relapsing-remitting multiple sclerosis
por: van Lierop, Zoë YGJ, et al.
Publicado: (2022)

Astrocyte-Derived Tissue Transglutaminase Interacts with Fibronectin: A Role in Astrocyte Adhesion and Migration?
por: van Strien, Miriam E., et al.
Publicado: (2011)

Tissue Transglutaminase in Marmoset Experimental Multiple Sclerosis: Discrepancy between White and Grey Matter
por: Espitia Pinzon, Nathaly, et al.
Publicado: (2014)

Astrocyte-derived tissue Transglutaminase affects fibronectin deposition, but not aggregation, during cuprizone-induced demyelination
por: Espitia Pinzon, Nathaly, et al.
Publicado: (2017)

Thinking about the action potential: the nerve signal as a window to the physical principles guiding neuronal excitability
por: Drukarch, Benjamin, et al.
Publicado: (2023)

The majority of natalizumab-treated MS patients have high natalizumab concentrations at time of re-dosing
por: van Kempen, Zoé LE, et al.
Publicado: (2017)

gMS-Classifier1 does not predict disability progression in multiple sclerosis
por: van Rossum, Johannis A, et al.
Publicado: (2018)

Switching natalizumab to fingolimod within 6 weeks reduces recurrence of disease activity in MS patients
por: Leurs, Cyra E, et al.
Publicado: (2017)

Fronto-limbic disconnection in patients with multiple sclerosis and depression
por: van Geest, Quinten, et al.
Publicado: (2018)

Gray matter networks and cognitive impairment in multiple sclerosis
por: Rimkus, Carolina M, et al.
Publicado: (2018)

In vivo assessment of neuroinflammation in progressive multiple sclerosis: a proof of concept study with [(18)F]DPA714 PET
por: Hagens, Marloes H. J., et al.
Publicado: (2018)

Information processing speed in multiple sclerosis: Relevance of default mode network dynamics
por: van Geest, Q., et al.
Publicado: (2018)

Neuroaxonal and Glial Markers in Patients of the Same Age With Multiple Sclerosis
por: Loonstra, Floor C., et al.
Publicado: (2022)

Serum glial fibrillary acidic protein in natalizumab-treated relapsing-remitting multiple sclerosis: An alternative to neurofilament light
por: Wessels, Mark HJ, et al.
Publicado: (2023)

Contactin-1 and contactin-2 in cerebrospinal fluid as potential biomarkers for axonal domain dysfunction in multiple sclerosis
por: Chatterjee, Madhurima, et al.
Publicado: (2018)

Strategies towards in vivo imaging of active transglutaminase type 2 using positron emission tomography
por: van der Wildt, Berend, et al.
Publicado: (2016)

Association of Arachidonic Acid–Derived Lipid Mediators With Disease Severity in Patients With Relapsing and Progressive Multiple Sclerosis
por: Broos, Jelle Y., et al.
Publicado: (2023)

Diurnal Cortisol Secretion Is Not Related to Multiple Sclerosis-Related Fatigue
por: Malekzadeh, Arjan, et al.
Publicado: (2020)

The association between blood MxA mRNA and long-term disease activity in early multiple sclerosis
por: Coerver, Eline M. E., et al.
Publicado: (2022)

The plasma peptides of Alzheimer’s disease
por: Florentinus-Mefailoski, Angelique, et al.
Publicado: (2021)

Personalized B-cell tailored dosing of ocrelizumab in patients with multiple sclerosis during the COVID-19 pandemic
por: van Lierop, Zoë YGJ, et al.
Publicado: (2021)

Cannot write session to /tmp/vufind_sessions/sess_2k9ef7mcf2ek7p4i5l67ofupvs